Johnson & Johnson (NYSE:JNJ) Stock Sold Off Rep. Thomas H. Kean, Jr.

Posted by Lindsey Winhoffer on Jul 19th, 2026

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on July 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on June 29th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.
Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 6/29/2026.
Sold $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 6/29/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/24/2026.
Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/24/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/22/2026.
Sold $1,001 – $15,000 in shares of Gildan Activewear (NYSE:GIL) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 6/4/2026.
Purchased $1,001 – $15,000 in shares of Gildan Activewear (NYSE:GIL) on 6/2/2026.
Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 6/2/2026.

Johnson & Johnson Trading Up 1.2%

NYSE JNJ traded up $2.96 on Friday, reaching $252.93. The stock had a trading volume of 10,166,132 shares, compared to its average volume of 7,890,866. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a fifty day moving average price of $239.82 and a two-hundred day moving average price of $234.63. Johnson & Johnson has a 12-month low of $162.78 and a 12-month high of $269.43. The firm has a market capitalization of $608.86 billion, a price-to-earnings ratio of 29.31, a P/E/G ratio of 2.37 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.68 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Raymond James Financial upped their target price on shares of Johnson & Johnson from $258.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday. Bank of America increased their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. Finally, Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.30.

Get Our Latest Stock Report on Johnson & Johnson

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Auto Owners Insurance Co boosted its holdings in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $6,924,523,000. Capital World Investors purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $2,005,942,000. Diamant Asset Management Inc. boosted its holdings in shares of Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after buying an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why
Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation
Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity
Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call
Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.